ESR1 and neoplasm: To identify the largest possible group of patients who could benefit from existing endocrine treatments or new drugs targeting both wild-type and mutant ER, one should employ upfront DNA and RNA sequencing on metastatic tumor tissue to optimally relate treatment response to genomic and transcriptomic profiles.